The recognition of urologic disease is a primary care issue, whether we've know it or not

Article Type
Changed
Tue, 09/25/2018 - 14:55
Display Headline
The recognition of urologic disease is a primary care issue, whether we've know it or not
Article PDF
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Milton M. Lakin, MD, FACP
Section Head, Medical Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Publications
Page Number
S5
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Milton M. Lakin, MD, FACP
Section Head, Medical Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Milton M. Lakin, MD, FACP
Section Head, Medical Urology, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH

Article PDF
Article PDF
Page Number
S5
Page Number
S5
Publications
Publications
Article Type
Display Headline
The recognition of urologic disease is a primary care issue, whether we've know it or not
Display Headline
The recognition of urologic disease is a primary care issue, whether we've know it or not
Citation Override
Cleveland Clinic Journal of Medicine 2007 May;74(suppl 3):S5
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Tue, 07/31/2018 - 08:15
Un-Gate On Date
Tue, 07/31/2018 - 08:15
Use ProPublica
CFC Schedule Remove Status
Tue, 07/31/2018 - 08:15
Article PDF Media

Overactive bladder: Recognition requires vigilance for symptoms

Article Type
Changed
Tue, 07/31/2018 - 11:43
Display Headline
Overactive bladder: Recognition requires vigilance for symptoms
Article PDF
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Christopher T. Tallman, BS
Research Fellow, Mid-Michigan Health Centers, Jackson, MI

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Mr. Tallman and Ms. Page reported that they have no financial relationships that pose a potential conflict of interest with this article.

Publications
Topics
Page Number
S21-S29
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Christopher T. Tallman, BS
Research Fellow, Mid-Michigan Health Centers, Jackson, MI

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Mr. Tallman and Ms. Page reported that they have no financial relationships that pose a potential conflict of interest with this article.

Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Christopher T. Tallman, BS
Research Fellow, Mid-Michigan Health Centers, Jackson, MI

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Mr. Tallman and Ms. Page reported that they have no financial relationships that pose a potential conflict of interest with this article.

Article PDF
Article PDF
Page Number
S21-S29
Page Number
S21-S29
Publications
Publications
Topics
Article Type
Display Headline
Overactive bladder: Recognition requires vigilance for symptoms
Display Headline
Overactive bladder: Recognition requires vigilance for symptoms
Citation Override
Cleveland Clinic Journal of Medicine 2007 May;74(suppl 3):S21-S29
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment

Article Type
Changed
Tue, 07/31/2018 - 11:47
Display Headline
Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment
Article PDF
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Ms. Page reported that she has no financial relationships that pose a potential conflict of interest with this article.

Publications
Topics
Page Number
S54-S62
Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Ms. Page reported that she has no financial relationships that pose a potential conflict of interest with this article.

Author and Disclosure Information

Matt T. Rosenberg, MD
Medical Director, Mid-Michigan Health Centers, Jackson, MI

Diane K. Newman, RNC, MSN, CRNP
Penn Center for Continence and Pelvic Health, Division of Urology, University of Pennsylvania Health System, Philadelphia, PA

Shari A. Page, CFNP
Mid-Michigan Health Centers, Jackson, MI

Correspondence: Matt T. Rosenberg, MD, Mid-Michigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; matttoren@yahoo.com

Dr. Rosenberg reported that he has received consulting fees and honoraria from Indevus Pharmaceuticals/ESPRIT Pharma, Pfizer, and GlaxoSmithKline for consulting, teaching/speaking, and serving on advisory committees; honoraria and consulting fees from Verathon Medical for consulting and serving on advisory committees; honoraria from Eli Lilly and Auxilium Pharmaceuticals for teaching/speaking; a research grant from Sanofi-Aventis; and consulting fees and honoraria from Ortho-McNeil for consulting and teaching/speaking.

Ms. Newman reported that she has received honoraria from Watson Pharmaceuticals, Pfizer, Astellas Pharma, GlaxoSmithKline, Novartis, and SCA Personal Care for teaching/speaking, as well as for serving on an advisory committee (for Watson) and for consulting (for SCA Personal Care).

Ms. Page reported that she has no financial relationships that pose a potential conflict of interest with this article.

Article PDF
Article PDF
Page Number
S54-S62
Page Number
S54-S62
Publications
Publications
Topics
Article Type
Display Headline
Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment
Display Headline
Interstitial cystitis/painful bladder syndrome: Symptom recognition is key to early identification, treatment
Citation Override
Cleveland Clinic Journal of Medicine 2007 May;74(suppl 3):S54-S62
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

In reply: Overactive bladder

Article Type
Changed
Mon, 09/10/2018 - 14:38
Display Headline
In reply: Overactive bladder
Article PDF
Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Issue
Cleveland Clinic Journal of Medicine - 72(7)
Publications
Topics
Page Number
544-545
Sections
Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 72(7)
Issue
Cleveland Clinic Journal of Medicine - 72(7)
Page Number
544-545
Page Number
544-545
Publications
Publications
Topics
Article Type
Display Headline
In reply: Overactive bladder
Display Headline
In reply: Overactive bladder
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Overactive bladder: Evaluation and management in primary care

Article Type
Changed
Fri, 09/07/2018 - 08:40
Display Headline
Overactive bladder: Evaluation and management in primary care
Article PDF
Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Issue
Cleveland Clinic Journal of Medicine - 72(2)
Publications
Topics
Page Number
149-156
Sections
Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Author and Disclosure Information

Matt T. Rosenberg, MD
Director, MidMichigan Health Centers, Jackson, MI

Roger R. Dmochowski, MD
Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

Address: Matt T. Rosenberg, MD, Director, MidMichigan Health Centers, 214 N. West Avenue, Jackson, MI 49201; e-mail matttoren@yahoo.com

Dr. Rosenberg has indicated that he is on the speakers’ bureau of Watson, Pfizer, and Ortho-McNeil, is a consultant for Pfizer and Ortho-McNeil, and has received grant or research support from Ortho-McNeil.

Dr. Dmochowski has indicated that he is a consultant for Watson and Indevus.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Article PDF
Article PDF
Related Articles
Issue
Cleveland Clinic Journal of Medicine - 72(2)
Issue
Cleveland Clinic Journal of Medicine - 72(2)
Page Number
149-156
Page Number
149-156
Publications
Publications
Topics
Article Type
Display Headline
Overactive bladder: Evaluation and management in primary care
Display Headline
Overactive bladder: Evaluation and management in primary care
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media